Current Affairs Topics Archive
International Relations Economics Polity & Governance Environment & Ecology Science & Technology Internal Security Geography Social Issues Art & Culture Modern History

CDSCO issues advisory to prevent misleading promotion of prescription drugs for obesity

March 11, 2026 6 min read Polity & Governance Science & Technology GS2 (Health Governance Regulatory Bodies) GS3 (Science & Technology)
On This Page ▼

What Happened

  • The Central Drugs Standard Control Organisation (CDSCO) issued an advisory on March 11, 2026, directing pharmaceutical companies not to engage in any promotional activity — direct or indirect — for GLP-1 receptor agonist drugs approved for obesity and metabolic disorder management.
  • CDSCO had received intelligence that some pharma companies were running digital outreach campaigns, "disease awareness" drives, and influencer engagements that functioned as surrogate advertisements for prescription-only GLP-1 drugs such as semaglutide (marketed as Ozempic/Wegovy) and tirzepatide (Mounjaro).
  • The advisory explicitly stated that "awareness campaigns that function as surrogate advertisements for prescription-only drugs" are impermissible under the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.
  • Any promotion exaggerating therapeutic efficacy, suggesting guaranteed weight-loss outcomes, or inducing consumer demand for pharmacological obesity therapy may attract regulatory action.
  • The advisory coincides with the expiry of the Indian patent on semaglutide on March 20, 2026, after which 30+ Indian generic versions are expected to flood the market at a fraction of current prices.

Static Topic Bridges

CDSCO: India's Central Drug Regulatory Authority

The Central Drugs Standard Control Organisation is the national regulatory body for pharmaceuticals and medical devices in India, functioning under the Directorate General of Health Services, Ministry of Health and Family Welfare. CDSCO's mandate derives primarily from the Drugs and Cosmetics Act, 1940 and the Medical Devices Rules, 2017. It exercises regulatory functions over: approval of new drugs and clinical trials, standards for drug quality and safety, import licensing, and advertising compliance. The Drugs Controller General of India (DCGI) heads CDSCO and is the licensing authority for new drugs, blood products, vaccines, and medical devices. State-level Drug Authorities handle manufacturing licences and retail-level enforcement.

  • CDSCO operates under the Drugs and Cosmetics Act, 1940 — the primary legislation governing drug manufacture, distribution, and sale in India.
  • Schedule H and Schedule H1 of the Drugs and Cosmetics Rules, 1945 classify drugs requiring a doctor's prescription for dispensing; Schedule H1 covers particularly sensitive drugs (including certain antibiotics, habit-forming drugs) with additional record-keeping requirements.
  • GLP-1 agonists (semaglutide, tirzepatide) approved for obesity are classified as Schedule H prescription drugs — they cannot be dispensed without a prescription and cannot be promoted to the general public.
  • DCGI approved semaglutide (injectable) in January 2026; approval for obesity indication distinguishes it from the earlier diabetes indication.

Connection to this news: CDSCO's advisory enforces the prescription-drug advertising bar that Schedule H classification imposes. The surge of interest in GLP-1 drugs — especially ahead of the generic entry — created incentives for pharma companies to run quasi-promotional "awareness" campaigns, which the advisory explicitly terms a regulatory violation.

Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954

The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 (DMROA) is the principal legislation restricting drug promotion in India. Passed on April 30, 1954, it prohibits advertisements that: (a) suggest a drug can treat any of 54 specified diseases (including cancer, diabetes, and epilepsy); (b) attribute magical or supernatural properties to remedies; or (c) promote drugs in a manner that fosters uncontrolled self-medication. While the DMROA was initially focused on quackery and magic remedies, its scope extends to all drugs. Penalties for violation: first offence — up to 2 years imprisonment and fine up to ₹10 lakh; subsequent offences — up to 5 years and fine up to ₹50 lakh (post-2020 amendments).

  • Section 3: Bans advertisements for drugs claiming to treat miscarriage, conception, menstrual disorders, or the 54 Schedule diseases.
  • Section 4: Bans magic remedies claiming supernatural efficacy.
  • "Surrogate advertising" — where a company promotes brand recall under the guise of "awareness" without naming the specific drug — is treated as a violation under the Drugs and Cosmetics Rules.
  • The Uniform Code of Pharmaceutical Marketing Practices (UCPMP), 2024 (strengthened version) provides additional guidelines against inducements to prescribers and patients.

Connection to this news: CDSCO's advisory draws directly on the DMROA and Drugs Rules framework, treating GLP-1 "awareness campaigns" as surrogate advertisements that violate the prohibition on prescription-drug promotion to the general public.

GLP-1 Receptor Agonists: Science and Regulatory Context

Glucagon-like peptide-1 (GLP-1) is a gut-derived incretin hormone that stimulates insulin secretion, inhibits glucagon release, and — critically — induces satiety signals in the brain. GLP-1 receptor agonists (GLP-1 RAs) are synthetic analogues of this hormone, originally developed to treat Type 2 diabetes (by reducing HbA1c), and subsequently approved for chronic weight management and cardiovascular risk reduction. Semaglutide (Novo Nordisk) — marketed as Ozempic (diabetes) and Wegovy (obesity) — is the most prominent GLP-1 RA, credited with producing 15-20% body weight reduction in clinical trials. Tirzepatide (Eli Lilly's Mounjaro) is a dual GIP/GLP-1 agonist showing even greater efficacy.

  • Mechanism: GLP-1 RAs slow gastric emptying, reduce appetite via hypothalamic signalling, and improve glycaemic control.
  • Semaglutide patent in India: Expires March 20, 2026 — enabling Indian generic manufacturers to produce cheaper versions.
  • Expected generic price: Monthly dose cost projected to fall from current ~$300+ to ~$40-77 over the next year.
  • Obesity in India: The National Family Health Survey (NFHS-5) found 24% of women and 23% of men are overweight or obese (BMI ≥25).
  • Obesity is classified as a comorbidity for Type 2 diabetes, hypertension, and cardiovascular disease — all rising rapidly in India's epidemiological transition.

Connection to this news: The imminent generic entry of semaglutide dramatically increases the commercial incentive for pharmaceutical companies to build brand awareness for GLP-1 drugs before patent expiry — which is precisely what CDSCO's advisory moves to prevent.

Pharmaceutical Advertising Regulations: A Tiered Framework

India's drug advertising regulatory framework operates at three levels. First, the DMROA 1954 sets the primary statutory bar on disease-cure claims and surrogate advertising. Second, the Drugs and Cosmetics Act 1940 and Rules 1945 establish the Schedule H/H1 prescription-only framework and empower CDSCO to take action against violations. Third, the Uniform Code of Pharmaceutical Marketing Practices (UCPMP) — a voluntary code progressively strengthened since 2015 and made effectively mandatory via the National Pharmaceutical Pricing Authority (NPPA) — governs industry conduct toward medical practitioners (e.g., banning gifts, sponsored hospitality). Enforcement, however, has historically been patchy: CDSCO issues advisories and can initiate prosecution, but actual convictions under DMROA are rare.

  • Direct-to-consumer (DTC) advertising of prescription drugs: Completely prohibited in India (unlike the United States, which permits DTC for prescription drugs).
  • India is one of the few major economies where DTC prescription drug advertising is banned outright — aligning with WHO guidelines.
  • "Disease awareness" campaigns are legally permissible if they are genuinely informational and brand-neutral, but become illegal when they create brand recall for a specific prescription product.
  • Social media influencer campaigns: The advisory explicitly targets this channel, reflecting regulator concern about digital-era drug promotion.

Connection to this news: The CDSCO advisory reinforces India's DTC advertising ban in the specific, high-commercial-interest context of obesity drugs — filling a regulatory gap that was emerging as the GLP-1 market heated up ahead of the patent cliff.

Key Facts & Data

  • CDSCO: Under Directorate General of Health Services, Ministry of Health and Family Welfare
  • Governing legislation: Drugs and Cosmetics Act, 1940; DMROA, 1954
  • GLP-1 agonists covered: Semaglutide (Ozempic/Wegovy), Tirzepatide (Mounjaro) and similar molecules
  • Regulatory classification: Schedule H prescription drugs — no OTC sale, no public advertising
  • Semaglutide Indian patent expiry: March 20, 2026
  • Expected generics: 30+ Indian manufacturers expected to launch generic semaglutide
  • Projected generic price: ~₹3,400–₹6,500/month (vs. ₹25,000+ for branded)
  • Obesity prevalence in India (NFHS-5): ~24% women, ~23% men (BMI ≥25)
  • DMROA 1954 penalties (post-2020): First offence — 2 years + ₹10 lakh fine; repeat — 5 years + ₹50 lakh
  • India's DTC prescription drug advertising: Prohibited (unlike USA)
  • UCPMP: Voluntary-cum-mandatory code governing pharma marketing practices